[HTML][HTML] Targeting interleukin-6 (IL-6) sensitizes anti-PD-L1 treatment in a colorectal cancer preclinical model
J Li, J Xu, X Yan, K Jin, W Li… - Medical science monitor …, 2018 - ncbi.nlm.nih.gov
Background Limited efficacy of immune checkpoint blockades was observed in clinical trials
in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin-6 (IL …
in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin-6 (IL …
Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
J Li, J Xu, X Yan, K Jin, W Li, R Zhang - Medical Science Monitor …, 2018 - europepmc.org
BACKGROUND Limited efficacy of immune checkpoint blockades was observed in clinical
trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin …
trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin …
Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
J Li, J Xu, X Yan, K Jin, W Li… - … medical journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
BACKGROUND Limited efficacy of immune checkpoint blockades was observed in clinical
trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin …
trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin …
[引用][C] Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
J Li, X Yan, K Jin, W Li - basic.medscimonit.com
Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
J Li, J Xu, X Yan, K Jin, W Li, R Zhang - Medical Science Monitor, 2018 - medscimonit.com
BACKGROUND: Limited efficacy of immune checkpoint blockades was observed in clinical
trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin …
trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin …
[PDF][PDF] Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
AJ Li - Med Sci Monit, 2018 - pdfs.semanticscholar.org
Background: Limited efficacy of immune checkpoint blockades was observed in clinical trials
in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin-6 (IL …
in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin-6 (IL …
Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
J Li, J Xu, X Yan, K Jin, W Li, R Zhang - Medical Science Monitor, 2018 - medscimonit.com
BACKGROUND: Limited efficacy of immune checkpoint blockades was observed in clinical
trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin …
trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin …